Detailed information for compound 171147

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 355.474 | Formula: C21H29N3O2
  • H donors: 1 H acceptors: 1 LogP: 5.73 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: [N-]=[N+]=NCCCCCc1cc(O)c2c(c1)OC([C@H]1[C@H]2CC(=CC1)C)(C)C
  • InChi: 1S/C21H29N3O2/c1-14-8-9-17-16(11-14)20-18(25)12-15(7-5-4-6-10-23-24-22)13-19(20)26-21(17,2)3/h8,12-13,16-17,25H,4-7,9-11H2,1-3H3/t16-,17-/m1/s1
  • InChiKey: NWUHIDITIWXYML-IAGOWNOFSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cannabinoid receptor 1 (brain) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Loa Loa (eye worm) hypothetical protein 0.8563 1 0.5
Onchocerca volvulus 0.8563 1 0.5
Schistosoma mansoni sodium-bile acid cotransporter related 0.8563 1 1
Echinococcus multilocularis sodium bile acid cotransporter 0.8563 1 0.5
Echinococcus granulosus sodium bile acid cotransporter 0.8563 1 0.5
Echinococcus multilocularis sodium bile acid cotransporter 0.8563 1 0.5
Echinococcus multilocularis sodium bile acid cotransporter 0.8563 1 0.5
Echinococcus granulosus sodium bile acid cotransporter 0.8563 1 0.5
Echinococcus granulosus sodium bile acid cotransporter 0.8563 1 0.5
Schistosoma mansoni sodium-bile acid cotransporter 0.5091 0.3179 0.3179

Activities

Activity type Activity value Assay description Source Reference
ED50 (functional) = 0.1 mg kg-1 Antinociception of the compound measured in terms of the maximum possible effect (MPE)on latency by mouse tail-flick assay ChEMBL. 1323683
ED50 (functional) = 0.1 mg kg-1 Antinociception of the compound measured in terms of the maximum possible effect (MPE)on latency by mouse tail-flick assay ChEMBL. 1323683
ED50 (functional) = 0.2 mg kg-1 Compound was evaluated by in vivo administration for its ability to produce sedation ChEMBL. 1323683
ED50 (functional) = 0.2 mg kg-1 Compound was evaluated by in vivo administration for its ability to produce sedation ChEMBL. 1323683
ED50 (functional) = 0.8 mg kg-1 Compound was evaluated by in vivo administration for its ability to produce hypothermia (change in temperature) ChEMBL. 1323683
ED50 (functional) = 0.8 mg kg-1 Induction of ring immobility (catalepsy), measured by in vivo administration of drug in mouse ChEMBL. 1323683
ED50 (functional) = 0.8 mg kg-1 Compound was evaluated by in vivo administration for its ability to produce hypothermia (change in temperature) ChEMBL. 1323683
ED50 (functional) = 0.8 mg kg-1 Induction of ring immobility (catalepsy), measured by in vivo administration of drug in mouse ChEMBL. 1323683
Immobility (functional) = 57 % Induction of ring immobility (catalepsy), measured by in vivo administration of drug in mouse ChEMBL. 1323683
Immobility (functional) = 57 % Induction of ring immobility (catalepsy), measured by in vivo administration of drug in mouse ChEMBL. 1323683
Inhibition (functional) = 73 % Compound was evaluated by in vivo administration for Percent inhibition of locomotion in mice ChEMBL. 1323683
Inhibition (functional) = 73 % Compound was evaluated by in vivo administration for Percent inhibition of locomotion in mice ChEMBL. 1323683
Inhibition (functional) = 100 % Percent inhibition of the compound measured in terms of the maximum possible effect (MPE)on latency by mouse tail-flick assay ChEMBL. 1323683
Inhibition (functional) = 100 % Percent inhibition of the compound measured in terms of the maximum possible effect (MPE)on latency by mouse tail-flick assay ChEMBL. 1323683
Ki (binding) = 19 nM Binding affinity to CB1 receptor (unknown origin) ChEMBL. 17521177
Ki (binding) = 19 nM Binding affinity to CB1 receptor (unknown origin) ChEMBL. 17521177

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

2 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.